论文部分内容阅读
[目的]分析莫西沙星干预治疗对多重耐药肺结核(MDR-TB)患者血清降钙素原(PCT)和可溶性髓系细胞触发受体-1(sTREM-1)水平的影响.[方法]连续性纳入140例MDR-TB患者,随机等分为莫西沙星组(n=70)和对照组(n=70),动态观察治疗后2个月和6个月血清PCT和sTREM-1水平改变,以及临床治愈情况.[结果]治疗6个月后,观察组有效率为85.7％(60/70)显著高于对照组的65.7％(46/70),差异具有统计学意义(x 2=5.962,P=0.015＜0.05).观察组在治疗后血清sTREM-1和PCT水平明显下降,血清sTREM-1在2个月和6个月两个时间点水平明显低于对照组患者,差异均具有统计学意义(均P＜0.05),而血清PCT水平在治疗6个月后明显低于对照组患者,差异具有统计学意义(P＜0.05).莫西沙星组患者无论是有效亚组还是无效亚组,血清PCT和sTREM-1水平在治疗后6个月与治疗前比较,差异均有统计学意义(P＜0.05).而对照组患者,治疗后PCT并没有明下降趋势,而sTREM-1水平虽然有所下降,但并无明显统计学差异(P＞0.05).[结论]莫西沙星可以有效降低MRD-TB患者血清PCT和sTREM-1水平,可提高其治疗有效率.“,”[Objective]To evaluate the effect of moxifloxacin intervention therapy on serum PCT and sTREM-1 in patients with multiple drug resistance tuberculosis(MDR-TB).[Methods]One hundred and forty patients with MDR-TB were enrolled in this study and randomly divided into two groups:the moxifloxacin group(n=70)and the control group.Dynamic changes of serum PCT and sTREM-1 levels and the clinical efficacy were observed in 2 and 6 months after treatment.[Results]After 6 months of treatment,the effective rate of the observation group was 85.7 ％ (60/70),which was significantly higher than that of the control group 65.7％ (46/70),and the difference was statistically significant (x2 =5.962,P =0.015＜0.05).The levels of serum sTREM-1 and PCT were significantly decreased in the observation group after treatment,the serum sTREM-1 level was significantly lower than that of the control group at 2 and 6 months,and the difference was statistically significant (mean P ＜0.05);the serum PCT level was significantly lower than that the control group after 6 months of treatment,the difference was statistically significant (P ＜0.05).The differences of the serum PCT and sTREM-1 levels of Moxifloxacin group(both in the effective subgroup or ineffective subgroup) were statistically significant 6 months before or after treatment (P ＜0.05);In the control group,PCT did not show a clear downward trend after treatment,while the level of sTREM-1 was decreased,but there was no significant difference(P ＞0.05).[Conclusion]Moxifloxacin can effectively reduce serum PCT and sTREM-1 levels in patients with MRD-TB and can improve the treatment efficiency.